IRIS PubliCatt

Di Giambenedetto, Simona
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.467
EU - Europa 7.044
AS - Asia 1.272
AF - Africa 45
SA - Sud America 21
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 8
Totale 15.866
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.424
DE - Germania 1.877
SE - Svezia 1.474
CN - Cina 812
PL - Polonia 744
FR - Francia 723
IT - Italia 703
UA - Ucraina 596
IE - Irlanda 430
IN - India 227
FI - Finlandia 178
GB - Regno Unito 171
TR - Turchia 65
IR - Iran 45
BE - Belgio 38
CA - Canada 29
HK - Hong Kong 28
RU - Federazione Russa 28
JP - Giappone 24
NL - Olanda 19
SG - Singapore 19
CI - Costa d'Avorio 17
CH - Svizzera 13
CM - Camerun 9
ES - Italia 9
KZ - Kazakistan 9
BR - Brasile 8
EU - Europa 8
MX - Messico 8
AU - Australia 7
CL - Cile 7
KR - Corea 7
RO - Romania 7
VN - Vietnam 7
TW - Taiwan 6
AT - Austria 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
DK - Danimarca 4
GR - Grecia 4
NG - Nigeria 4
EG - Egitto 3
PA - Panama 3
PE - Perù 3
TH - Thailandia 3
BZ - Belize 2
CO - Colombia 2
CZ - Repubblica Ceca 2
EE - Estonia 2
ID - Indonesia 2
IM - Isola di Man 2
MA - Marocco 2
MY - Malesia 2
NO - Norvegia 2
PH - Filippine 2
PK - Pakistan 2
PT - Portogallo 2
TZ - Tanzania 2
YE - Yemen 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BN - Brunei Darussalam 1
BT - Bhutan 1
BY - Bielorussia 1
CY - Cipro 1
ET - Etiopia 1
GL - Groenlandia 1
HR - Croazia 1
IL - Israele 1
IS - Islanda 1
KE - Kenya 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
NZ - Nuova Zelanda 1
SC - Seychelles 1
TN - Tunisia 1
UG - Uganda 1
ZW - Zimbabwe 1
Totale 15.866
Salva come PNG Salva come JPEG
Città #
Chandler 1.886
Ashburn 652
Kraków 599
Dublin 423
Jacksonville 416
San Mateo 381
New York 374
Nanjing 227
Wilmington 214
Ann Arbor 178
Milan 176
Boston 175
Dearborn 164
Houston 152
Warsaw 143
Cattolica 124
Princeton 123
Lawrence 122
Nürnberg 110
Woodbridge 105
Redwood City 103
Beijing 102
Nanchang 95
Marseille 75
Rome 75
Redmond 74
Seattle 73
Izmir 65
Fairfield 57
Lancaster 56
Bremen 51
Boardman 50
Shenyang 50
Mountain View 49
Norwalk 45
Chicago 43
Changsha 41
Kunming 41
Helsinki 40
Pune 40
Brussels 38
Hebei 37
University Park 37
Los Angeles 36
Augusta 32
Verona 31
Munich 28
Leawood 27
Tianjin 27
Fremont 25
Cambridge 24
Jiaxing 24
Hangzhou 23
Andover 22
Jinan 22
Shanghai 22
Guangzhou 21
Hong Kong 20
Washington 20
Kish 19
Philadelphia 18
Abidjan 17
Falls Church 16
Hefei 16
Ottawa 15
Edinburgh 13
Zhengzhou 13
San Jose 12
Busto Arsizio 11
Changchun 11
London 11
Simi Valley 11
Amsterdam 10
Singapore 10
Detroit 9
Fuzhou 9
Toronto 9
Turin 9
Sacramento 8
Tavagnacco 8
Indiana 7
Almaty 6
Atlanta 6
Las Vegas 6
Phoenix 6
San Francisco 6
Tappahannock 6
Auburn Hills 5
Baltimore 5
Berlin 5
Clearwater 5
Costa Mesa 5
Hanoi 5
Hanover 5
Monmouth Junction 5
New Delhi 5
Paris 5
Phoenixville 5
Siena 5
São Paulo 5
Totale 8.848
Salva come PNG Salva come JPEG
Nome #
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR 314
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 191
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 170
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 169
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 164
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 159
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 152
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 144
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 142
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 137
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 135
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 131
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 129
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 129
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 125
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 125
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 121
Variability of raltegravir plasma levels in the clinical setting 117
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 117
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 116
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 113
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 111
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 107
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 104
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 102
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 102
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 101
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 101
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 101
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 100
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 100
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 99
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 99
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 98
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 96
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 96
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 94
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 93
Effect of aging and human immunodeficiency virus infection on cognitive abilities 93
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 93
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 93
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 93
Cognitive reserve and neuropsychological functioning in older HIV-infected people 93
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 92
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 91
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 91
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 90
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 90
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 89
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 89
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 89
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 89
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 88
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 88
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 87
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 87
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 87
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 86
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 84
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 83
Mortality in patients with early- or late-onset candidaemia 83
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 83
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 83
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 82
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 82
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy 80
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 80
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 80
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 78
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 78
Mortality in patients, with early-or late-onset candidaemia 78
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 77
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 77
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 76
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? 76
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 76
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 76
Evolution and predictors of HIV type 1 drug resistance in patients failing combination antiretroviral therapy in Italy 75
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 75
Lipid-lowering effect of tenofovir in HIV-infected patients 74
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 73
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 73
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 73
Long term follow-up of Nevirapine-treated patients in a single centre cohort 72
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 72
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 72
Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort 71
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 71
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study 70
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 70
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 70
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 69
Interpretation systems for genotypic drug resistance of HIV-1 68
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study 68
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 68
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study 68
Mortality in patients with early- or late-onset candidaemia 67
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 67
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 65
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors 65
Totale 9.730
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.079
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.079
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019189 0 0 0 0 0 0 0 0 0 0 132 57
2019/20201.791 408 73 104 74 125 187 107 70 132 111 244 156
2020/20211.423 112 155 33 142 165 85 134 24 210 77 246 40
2021/20222.108 174 125 40 173 76 63 96 376 79 151 298 457
2022/20234.750 650 729 362 682 373 586 139 393 584 48 146 58
2023/20242.005 94 661 51 311 96 502 116 46 57 68 3 0
Totale 16.178